Patents by Inventor Martin E. Sanders

Martin E. Sanders has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RXR agonist salt form, polymorphs thereof, and uses thereof
    Patent number: 11919848
    Abstract: Provided herein are salt and solid forms of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, including a Tris salt form of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, and polymorphs thereof, methods of preparing the compounds, and their uses.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: March 5, 2024
    Assignee: Io Therapeutics, Inc.
    Inventors: Vidyasagar Vuligonda, Martin E. Sanders, Shanming Kuang, Harsh Shailesh Shah
  • METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT
    Publication number: 20240050479
    Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
    Type: Application
    Filed: October 5, 2023
    Publication date: February 15, 2024
    Inventors: Martin E. Sanders, Vidyasagar Vuligonda
  • Use of an RXR agonist and taxanes in treating Her2+ cancers
    Patent number: 11896558
    Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered. Related compositions and combination are also disclosed.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: February 13, 2024
    Assignees: Io Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • Methods of using RAR? agonists for cancer treatment
    Patent number: 11793835
    Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: October 24, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Martin E. Sanders, Vidyasagar Vuligonda
  • RAR selective agonists in combination with immune modulators for cancer immunotherapy
    Patent number: 11786555
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor agonist.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: October 17, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11779558
    Abstract: Disclosed herein are methods for culturing CAR-modified immune cells with at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: October 10, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • RXR AGONIST SALT FORM, POLYMORPHS THEREOF, AND USES THEREOF
    Publication number: 20230295069
    Abstract: Provided herein are salt and solid forms of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, including a Tris salt form of (2E,4E)-3-methyl-5-((1S,2S)-2-methyl-2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopropyl)penta-2,4-dienoic acid, and polymorphs thereof, methods of preparing the compounds, and their uses.
    Type: Application
    Filed: March 14, 2023
    Publication date: September 21, 2023
    Inventors: Vidyasagar Vuligonda, Martin E. Sanders, Shanming Kuang, Harsh Shailesh Shah
  • TREATMENT OF AUTOIMMUNE DISEASES WITH COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES
    Publication number: 20230293506
    Abstract: The present specification provides methods of treating a transplant rejection, pulmonary fibrosis, or glomerulonephritis with a combination of a RXR agonist and a thyroid hormone.
    Type: Application
    Filed: May 19, 2023
    Publication date: September 21, 2023
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11737996
    Abstract: Disclosed herein are methods for treating cancer comprising administering CAR-modified immune cells and at least one Retinoic Acid Receptor and/or Retinoid X Receptor active agent.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: August 29, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 11690831
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: July 4, 2023
    Assignee: IO Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • Treatment of autoimmune diseases with combinations of RXR agonists and thyroid hormones
    Patent number: 11690832
    Abstract: The present specification provides methods of treating autoimmune diseases with a combination of a RXR agonist and a thyroid hormone.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: July 4, 2023
    Assignee: IO Therapeutics
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • USE OF AN RXR AGONIST IN TREATING DRUG RESISTANT HER2+ CANCERS
    Publication number: 20230172890
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Application
    Filed: December 7, 2022
    Publication date: June 8, 2023
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • USE OF AN RXR AGONIST AND TAXANES IN TREATING HER2+ CANCERS
    Publication number: 20230172872
    Abstract: The present specification provides improved methods of treating Her2+ cancers in which an RXR agonist and a taxane are administered to a subject having a Her2+ cancer. Thyroid hormone and other anticancer agents may also be administered.
    Type: Application
    Filed: December 7, 2022
    Publication date: June 8, 2023
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
    Patent number: 11648223
    Abstract: Disclosed herein are methods for treating cancer comprising administering at least one immune checkpoint inhibitor and at least one Retinoic Acid Receptor or Retinoid X Receptor active agent.
    Type: Grant
    Filed: March 3, 2022
    Date of Patent: May 16, 2023
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
    Publication number: 20230126763
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Application
    Filed: November 2, 2022
    Publication date: April 27, 2023
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF DISEASE WITH ESTERS OF SELECTIVE RXR AGONISTS
    Publication number: 20230129034
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Application
    Filed: November 2, 2022
    Publication date: April 27, 2023
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • METHODS OF USING RARy AGONISTS FOR CANCER TREATMENT
    Publication number: 20230095368
    Abstract: The invention discloses novel RAR gamma selective agonists used in the treatment of cancer. The invention also discloses administration of RAR gamma selective agonists to mammals, including humans for the purpose of selectively activating RAR gamma receptor and treat cancer by way of activating tumor infiltrating lymphocytes.
    Type: Application
    Filed: November 23, 2022
    Publication date: March 30, 2023
    Inventors: Martin E. Sanders, Vidyasagar Vuligonda
  • Treatment of disease with esters of selective RXR agonists
    Patent number: 11517549
    Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.
    Type: Grant
    Filed: September 20, 2018
    Date of Patent: December 6, 2022
    Assignee: Io Therapeutics, Inc.
    Inventors: Roshantha A. Chandraratna, Martin E. Sanders
  • TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS
    Publication number: 20220370386
    Abstract: The present specification provides RXR agonists with both remyelination promotion and immunomodulatory activities, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat a demyelination-related disorder by both promoting remyelination of neurons and modulating the immune system.
    Type: Application
    Filed: July 7, 2022
    Publication date: November 24, 2022
    Inventors: Roshantha A. Chandraratna, Ethan Dmitrovsky, Elizabeth Nowak, Randolph Noelle, Martin E. Sanders
  • USE OF AN RXR AGONIST IN TREATING HER2+ CANCERS
    Publication number: 20220211652
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise and RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Application
    Filed: December 30, 2021
    Publication date: July 7, 2022
    Inventors: Martin E. Sanders, Powel H. Brown